Oluyemi Okupe Sells 9,217 Shares of Hims & Hers Health (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 9,217 shares of the firm’s stock in a transaction dated Friday, March 20th. The stock was sold at an average price of $23.77, for a total transaction of $219,088.09. Following the transaction, the chief financial officer directly owned 318,789 shares in the company, valued at approximately $7,577,614.53. This represents a 2.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Oluyemi Okupe also recently made the following trade(s):

• On Tuesday, January 20th, Oluyemi Okupe sold 9,067 shares of Hims & Hers Health stock. The stock was sold at an average price of $30.34, for a total transaction of $275,092.78.
• On Monday, January 5th, Oluyemi Okupe sold 9,070 shares of Hims & Hers Health stock. The shares were sold at an average price of $33.79, for a total transaction of $306,475.30.

Hims & Hers Health Stock Performance

Shares of NYSE:HIMS opened at $21.39 on Wednesday. Hims & Hers Health, Inc. has a 12-month low of $13.74 and a 12-month high of $70.43. The company’s 50 day moving average price is $22.39 and its two-hundred day moving average price is $36.29. The firm has a market cap of $4.88 billion, a PE ratio of 41.95, a PEG ratio of 2.60 and a beta of 2.55. The company has a quick ratio of 1.70, a current ratio of 1.90 and a debt-to-equity ratio of 1.80.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, February 23rd. The company reported $0.08 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.06. The company had revenue of $617.82 million during the quarter, compared to the consensus estimate of $619.48 million. Hims & Hers Health had a net margin of 5.47% and a return on equity of 22.48%. The firm’s quarterly revenue was up 28.4% on a year-over-year basis. During the same period in the previous year, the business earned $0.11 earnings per share. Equities research analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Analyst Upgrades and Downgrades

HIMS has been the subject of a number of recent analyst reports. Zacks Research upgraded Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 25th. BTIG Research cut Hims & Hers Health from a “buy” rating to a “neutral” rating in a research report on Tuesday, February 24th. Truist Financial reaffirmed a “hold” rating and issued a $18.00 price target (down from $37.00) on shares of Hims & Hers Health in a research note on Tuesday, February 24th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hims & Hers Health in a research report on Monday, December 29th. Finally, TD Cowen reduced their price objective on shares of Hims & Hers Health from $20.00 to $17.00 and set a “hold” rating on the stock in a research note on Tuesday, February 24th. Three investment analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $31.29.

Institutional Investors Weigh In On Hims & Hers Health

A number of large investors have recently modified their holdings of HIMS. Quent Capital LLC bought a new position in shares of Hims & Hers Health in the 3rd quarter valued at $28,000. Binnacle Investments Inc acquired a new stake in Hims & Hers Health in the third quarter valued at about $28,000. Virtus Advisers LLC acquired a new stake in Hims & Hers Health in the second quarter valued at about $26,000. Hilltop National Bank bought a new position in Hims & Hers Health in the third quarter valued at about $35,000. Finally, Skandinaviska Enskilda Banken AB publ grew its position in Hims & Hers Health by 408.2% in the second quarter. Skandinaviska Enskilda Banken AB publ now owns 747 shares of the company’s stock valued at $37,000 after acquiring an additional 600 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.